Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TACR1 | P25103 | 3/20 | 0.45 |
| ▸ | GLP1R | P43220 | 2/20 | 0.44 |
| ▸ | REN | P00797 | 3/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.41 |
| ▸ | PPIB | P23284 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1434992 | 1.00 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2ATACR1GLP1R | |
| SCHEMBL1431568 | 0.86 | TACR1 (0.44) | TACR1XIAPPPIB | |
| SCHEMBL1432215 | 0.85 | TACR1 (0.45) | TACR1XIAP | |
| SCHEMBL1432283 | 0.85 | ALDH1A1 (0.49) | ALDH1A1MEN1KMT2APPIBOPRK1 | |
| Hydrochloric Acid SCHEMBL3256738 | 0.84 | TACR1 (0.46) | TACR1XIAPOPRK1 | |
| SCHEMBL1432153 | 0.84 | TACR1 (0.43) | MEN1KMT2ATACR1XIAPLMNA | |
| SCHEMBL1432083 | 0.82 | TACR1 (0.47) | TACR1XIAP | |
| SCHEMBL1432037 | 0.82 | TACR1 (0.47) | TACR1XIAP | |
| SCHEMBL1432276 | 0.80 | ALDH1A1 (0.45) | ALDH1A1MEN1KMT2APPIBUSP30 | |
| Trifluoroacetic Acid SCHEMBL1433925 | 0.80 | XIAP (0.45) | MEN1KMT2ATACR1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300428-A1 | AMINOPYRIDINE DERIVATIVES | Vantia Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| WO-2009133348-A1 | AMINOPYRIDINE DERIVATIVES | VANTIA LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | ALDH1A1 147/4885MEN1 3876/4885KMT2A 2435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.